Prostate specific antigen: a decade of discovery--what we have learned and where we are going.
about
Translational biomarker discovery in clinical metabolomics: an introductory tutorialA simple computer program for calculating PSA recurrence in prostate cancer patientsDifferences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donorsDiagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic reviewThe Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsEmerging PSA-based tests to improve screeningCancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancerProstate Cancer Associated Lipid Signatures in Serum Studied by ESI-Tandem Mass Spectrometryas Potential New BiomarkersA Bayesian hierarchical non-linear regression model in receiver operating characteristic analysis of clustered continuous diagnostic data.Detection of early prostate cancer using a hepsin-targeted imaging agent.Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocityDo serum biomarkers really measure breast cancer?Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancerCancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other CancersUsefulness of ultra-sensitive prostate-specific antigen following radical prostatectomy.Novel diagnostic biomarkers for prostate cancer.HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling.Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery.Modeling time resolved light propagation inside a realistic human head model.Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor.Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia.Diagnosis of local recurrence after radical prostatectomy.Is prostate biopsy essential to diagnose prostate cancer in the older patient with extremely high prostate-specific antigen?Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent[-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first reportBone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX scoreA Review on the Clinical Utility of PSA in Cancer ProstateRole of prostate-specific antigen change ratio at initial biopsy as a novel decision-making marker for repeat prostate biopsy.The value of screening tests for detection of prostate cancer in 1000 saudi menElectrochemical immunosensors for detection of cancer protein biomarkers.Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study.Rising prostate-specific antigen after primary prostate cancer therapy.Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsyQuantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissuesSerum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion.Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer ScreeningActivity-based protein profiling: the serine hydrolasesMolecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion frontLack of an Association between Neutrophil-to-Lymphocyte Ratio and PSA Failure of Prostate Cancer Patients Who Underwent Radical ProstatectomyOvercoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer.
P2860
Q24598642-453C563B-2789-442F-85DC-4255B09B65CEQ24797983-8C0AFB69-36BB-4696-AC81-337DE7A06D82Q24815497-7F632086-6418-4E39-AB5A-553BECE73193Q26748872-52046B9C-8F37-4E09-B7B2-C4DFC3183239Q26750672-6AD73623-C6E4-4190-9DAA-715B4B2994BBQ26828563-ECD44657-1928-40D2-A58F-E3F3CE4562CCQ26852766-4CE734D0-A349-4318-ADC2-93B6E60AF899Q28550619-852D0AC0-A3E4-4816-87E5-58C3C3AB91C2Q31004636-1C6A7CF4-D11E-446E-9116-30162A699B69Q33326514-D23F13A1-24E1-451F-8B43-E0D169490352Q33365802-9FF89692-34E0-4AC9-98AF-B0EF987BB382Q33454967-AACD3A5B-6A02-4DE8-9B1B-1FA0E8849DFFQ33566716-1C733873-B21D-41CF-9EA0-6307023715B2Q33624448-8191B7D3-6310-4327-991D-B881688265FFQ33932975-981DE2E5-304F-4356-806C-7BEF45AE39EAQ34231678-D481FE5E-1E8D-4F0F-93CB-B9CDB5392F61Q34438274-C190D872-F911-47F4-A331-DDFF6DA8E185Q34601463-33AFA4A8-ECC4-4588-8EA0-B6509C951996Q34649916-E4EFF6DE-85FC-4294-B656-ADA6F7F34EB5Q34680813-47CA3AC6-CF7B-4D3E-9AAB-F827A1D6A110Q35685850-199FB67E-2F51-4D5A-9A55-046241659E59Q35685876-4967D384-28A3-4CED-AC33-C363BBF877A8Q35775441-6886246D-4584-41B7-8D41-938941461105Q35966831-CC6488BA-107A-49A6-8BEC-6BC040716C97Q35969948-012E02BF-B3EC-4AC7-82C1-BE18858B9A13Q36055696-F8688ECE-72E4-4526-AB50-2936CDE48F02Q36084063-0C6E2B57-A27B-4C3A-8668-62945338648DQ36120412-21C49A0E-82AA-4B00-8FF3-AB0A887DEAB4Q36133950-12E31941-1965-4366-81AD-918D59472BD7Q36195062-54A0BC53-ECF4-4B46-B5A2-6284BFC9245CQ36346204-B6C26BB4-432E-4215-85AA-03A02CE69A71Q36395149-1D1669AA-1D57-49C5-86BD-C86A874A421DQ36544801-446E79C6-1F2F-4119-9624-F88FBAC0898DQ36646676-30CE9DF4-0DC0-4B3E-A510-B9C0C463617EQ36693206-D3268014-6898-4277-9DAF-0A05C3175AD4Q36706929-98D52F61-5AC8-42C0-8D76-FE00F5A303B6Q36773877-D0FA905A-F5FB-451C-9EDD-C4DF5406CDF1Q36848899-532A22C4-7B72-4815-BFB6-636DFE5DE982Q36864218-58F2976A-B1F2-4BC7-AE20-C5E4BDC70BE6Q37014389-7A377902-D5C7-4416-A7A7-075F09400BFF
P2860
Prostate specific antigen: a decade of discovery--what we have learned and where we are going.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Prostate specific antigen: a d ...... earned and where we are going.
@ast
Prostate specific antigen: a d ...... earned and where we are going.
@en
type
label
Prostate specific antigen: a d ...... earned and where we are going.
@ast
Prostate specific antigen: a d ...... earned and where we are going.
@en
prefLabel
Prostate specific antigen: a d ...... earned and where we are going.
@ast
Prostate specific antigen: a d ...... earned and where we are going.
@en
P2093
P1476
Prostate specific antigen: a d ...... earned and where we are going.
@en
P2093
Oesterling JE
Polascik TJ
P304
P356
10.1097/00005392-199908000-00003
P407
P577
1999-08-01T00:00:00Z